Acute leukemia, lymphomas, Hodgkin's disease, endometrial carcinoma, breast cancer, sarcomas.

Cyclophosphamide is classed as an alkylating agent of the nitrogen mustard type. An activated form of cyclophosphamide, phosphoramide mustard, alkylates or binds with many intracellular molecular structures, including nucleic acids. Its cytotoxic action is primarily due to cross-linking of strands of DNA and RNA, as well as to inhibition of protein synthesis. Cyclophosphamide is a potent immunosuppressant. It also causes marked and persistent inhibition of cholinesterase activity.

Absorption- Bioavailability: > 75%; Metabolism- Hepatic; Excretion- Renal, 5 to 25% unchanged. In dialysis: cyclophosphamide is dialyzable; Elimination Half Life: Unchanged drug—3 to 12 hours

Hemorrhagic cystitis, diabetes mellitus, renal and hepatic failure.

D

Contraindicated; cyclophosphamide can secreted into breast milk. One nursing infant case reported to have leukopenia. Other possible effect of immune system supression, or carcinogenesis can be expected.

Leukopenia, thrombocytopenia, alopecia, cystitis, nausea, vomiting, pulmonary fibrosis, cardiotoxicity, skin rash

1 to 5 mg/kg/day ORALLY, for both initial and maintenance dosing

Cyclophosphamide 100mg/L or 3.1g/L in D5W, 1.5% or less cyclophosphamide decomposition in 8 hours at 24 to 27 ℃ or 6 days at 5 ℃. Cyclophosphamide 4g/L in Sodium Chloride 0.9%, 3.5% cyclophosphamide decomposition in 24 hours at room temperature and 1% dec